Given the recent failures of clinical trials involving the enzymatic inhibitors of BACE1 to treat AD [39–41], downregulating the BACE1 expression via KLF5 inhibition or blocking the binding of KLF5 to BACE1 promoter might be alternative approaches. This evidence concerns the gene BACE1 and Alzheimer disease.